PGEN250117P2500
- 1.50
- 0.000.00%
Precigen Newsroom
Precigen Shares Are Trading Higher After HC Wainwright & Co. Raised Its Price Target on the Stock From $4 to $6.
Knight-Swift Transportation Posts Upbeat Earnings, Joins TAL Education, LSI Industries, GE Aerospace And Other Big Stocks Moving Higher On Thursday
H.C. Wainwright Maintains Precigen(PGEN.US) With Buy Rating, Raises Target Price to $6
Should You Invest in Precigen (PGEN)?
Precigen Analyst Ratings
Precigen's Strategic Advancements and Pipeline Developments Drive Buy Rating
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
Precigen Secures $79M Financing for 2025 Launch
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Stifel Maintains Precigen(PGEN.US) With Buy Rating
Stifel Thinks Precigen Stock Set to Rebound After Capital Secured, BLA Submitted
Precigen's Strategic Advances and Financial Strength Boost Market Position for PRGN-2012
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
Precigen Completes Submission of Biologics License Application for Respiratory Disease Treatment
Precigen Seeks FDA Priority Review for Gene Therapy Targeting Rare Respiratory Disease
Precigen Submits BLA With Request for Priority Review to FDA for PRGN-2012
Express News | Precigen Completes Submission of Bla With Request for Priority Review to the FDA for Prgn-2012 for the Treatment of Adults With Recurrent Respiratory Papillomatosis
Precigen Completes Submission of BLA With Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults With Recurrent Respiratory Papillomatosis
Precigen Price Target Lowered to $5 From $7 at JMP Securities